Shenlin Huang
About Shenlin Huang
Shenlin Huang, Ph.D. Executive Director at Biotheryx
Shenlin Huang, Ph.D. currently holds the position of Executive Director of Medicinal Chemistry at Biotheryx. He joined the company as Senior Director of Chemistry in June 2022 and was promoted to his current role in January 2024. In his role, Dr. Huang oversees the company's Medicinal Chemistry department, which includes responsibilities for database management, computational chemistry, and ADME/PK research.
Shenlin Huang, Ph.D. Education and Expertise
Dr. Shenlin Huang earned his Ph.D. in organic chemistry from the University of South Carolina. Following his doctorate, he conducted his postdoctoral training at North Carolina State University. His expertise lies particularly in the areas of medicinal chemistry, protein degradation, and the development of clinical compounds. His educational foundation has paved the way for a successful career in pharmaceutical and biomedical research.
Career Background of Shenlin Huang, Ph.D.
Before joining Biotheryx, Dr. Shenlin Huang served in several critical positions across notable pharmaceutical companies. He was a Group Leader at AbbVie Oncology Discovery where he led the protein degradation program. At Novartis Institutes for BioMedical Research, he was a Senior Research Investigator leading a team that designed, synthesized, and developed the FDA-approved drug BRAFTOVI. Additionally, Dr. Huang worked as a Senior Scientist at Johnson and Johnson Pharmaceutical, contributing to various clinical compounds.
Shenlin Huang, Ph.D. Achievements in Medicinal Chemistry
Throughout his career, Dr. Shenlin Huang has been a significant contributor to the field of medicinal chemistry. One of his major achievements includes leading the team at Novartis that developed BRAFTOVI, an FDA-approved drug. His work involves not only drug development but also advancements in protein degradation programs while at AbbVie. His contributions extend to several clinical compounds and have played a crucial role in the success of pharmaceutical research projects.